$484.03▾ 0.17%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$0.97cash per $1 profit
Healthy
Most of its reported profit shows up as real cash.
Valuation
37th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+12.4%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Vertex Pharmaceuticals Incorporated turns 97¢ of every reported profit-dollar into real cash. Most of its reported profit shows up as real cash. Revenue is growing at a steady pace. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$17.17
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin35.0%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$12.59B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days14 articles
6 bullish8 neutral0 bearish
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
VHT vs. PBE: Which Health Care ETF Is the Better Buy?- Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.